Abstract
Background The relationship between antibody levels (more generally, a scalar measure of immune protection) at the time of exposure to infection (so-called exposure-proximal correlates of protection) and the risk of infection given exposure is of central interest in evaluating the evolution of immune protection conferred by prior infection and/or vaccination. A version of the test-negative study design (TND), adapted from vaccine effectiveness studies, has been used to assess this relationship. However, the conditions under which such a study identifies the relationship between immune measurements and protection have not been defined.
Objective To evaluate the conditions for TNDs to estimate the relationship between antibody levels or a similar scalar measurement of immunity (hereafter exposure-proximal correlates of protection, COP) and the relative incidence rate of infection given exposure.
Method Individual-based transmission models, linking infection risk linearly and nonlinearly with COP value and accounting for waning immunity post-vaccination and –infection, were used. Simulations were performed of a TND with sampling on predetermined dates. Data from either one or multiple simulation days were analyzed using logistic regression and generalized additive models.
Result A correctly specified logistic regression model provided an unbiased estimate of the effectiveness of specific COP levels (analogous to vaccine effectiveness). Aggregating data across different simulation dates with incidence-density sampling also provided reliable estimates of protection. When, as is generally the case, the functional form relating COP level to protection is unknown, generalized additive models offer a more flexible alternative to traditional logistic regression approaches.
Conclusion A TND can validly estimate the relative effect of an immune COP at the time of exposure on the incidence rate of infection via logistic regression if the functional form of the effect is known and appropriately modeled or unknown a semiparametric approach. Future research should further examine the dynamics of immunity waning and boosting for more reliable inference.
Competing Interest Statement
C.B. and M. L. report consulting income from Janssen Pharmaceuticals. M.L. serves as Senior Advisor to the US CDC's Center for Forecasting and Outbreak Analytics. This paper is written in his academic capacity and may not represent the views of the CDC or any government agency.
Funding Statement
Z.Z., C.B. and M.L. were supported by the SeroNet program of the National Cancer Institute (Grant number: 1U01CA261277).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This is a simulation study with code available at
